Technical Analysis for ADAP - Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets in the form of peptides, which are short sequences of amino acids; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead product candidate includes NY-ESO, a cancer antigen, which is in Phase I/II clinical trials for the treatment of patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer, as well as for non-small cell lung cancer. It is also developing MAGE A-10 TCR that is in preclinical stage for the treatment of breast and lung cancer, and other solid tumors, as well as a TCR therapeutic candidate directed to Alpha Fetoprotein. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Medicine Biopharmaceutical Cancer Clinical Medicine Immunotherapy Solid Tumors Cancer Treatments Non Small Cell Lung Cancer Cancer Immunotherapy Virotherapy Ovarian Cancer Multiple Myeloma Melanoma Hematological Malignancies Adoptive Cell Transfer Oncolytics Biotech Tumors Of The Hematopoietic And Lymphoid Tissues Cancer Immunotherapy Products Esophageal Cancer Breast And Lung Cancer